<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36971919</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases.</ArticleTitle><Pagination><StartPage>1965</StartPage><EndPage>1979</EndPage><MedlinePgn>1965-1979</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06559-y</ELocationID><Abstract><AbstractText>Childhood-onset neuropsychiatric systemic lupus erythematosus (cNPSLE) with psychosis is a challenging manifestation of SLE. Pathogenic long-lived plasma cells (LLPCs) are not specifically targeted by standard immunosuppression and their persistence contributes to chronic autoimmunity. Bortezomib is approved for the treatment of multiple myeloma and has shown benefits in a variety of other antibody-mediated diseases. Bortezomib may be efficacious for severe or treatment-refractory cNPSLE through eradication of LLPCs, decreasing autoantibody production. We describe the first pediatric case series of five patients with unrelenting cNPSLE with psychosis who were treated safely and effectively with bortezomib between 2011 and 2017. Most patients had persistent cNPSLE with psychosis despite aggressive immunosuppression with methylprednisolone, cyclophosphamide, rituximab, and usually plasmapheresis. All patients demonstrated rapid clinical improvement in their psychotic manifestations with the ability to quickly taper immunosuppression after the introduction of bortezomib. No patient had a recurrence of overt psychosis during a follow-up period of 1-10&#xa0;years. Secondary hypogammaglobulinemia developed in all five patients and required immunoglobulin replacement. No other severe side effects or adverse events were observed. Bortezomib-mediated LLPC depletion is a promising therapy for severe recalcitrant cNPSLE with psychosis when used as adjunctive therapy to conventional immunosuppression, B-cell, and antibody-depleting therapies. After initiation of bortezomib, patients had rapid, demonstrable improvement in psychosis as well as reduction in glucocorticoids and antipsychotics. Further investigation is needed to determine the therapeutic role of bortezomib in severe cNPSLE and cSLE. We present a mini-review of the rationale for bortezomib use and novel B-cell immunomodulation in rheumatic disease.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Modica</LastName><ForeName>Renee F</ForeName><Initials>RF</Initials><Identifier Source="ORCID">0000-0001-5250-759X</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, University of Florida, Gainesville, FL, USA. modicar@peds.ufl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thatayatikom</LastName><ForeName>Akaluck</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7977-9237</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Rheumatology and Immunology, AdventHealth for Children, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell-Brunson</LastName><ForeName>Denise H</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-7736-6882</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elder</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-8820-5515</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>69G8BD63PP</RegistryNumber><NameOfSubstance UI="D000069286">Bortezomib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020945" MajorTopicYN="Y">Lupus Vasculitis, Central Nervous System</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069286" MajorTopicYN="N">Bortezomib</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bortezomib</Keyword><Keyword MajorTopicYN="N">Central nervous system (CNS) lupus</Keyword><Keyword MajorTopicYN="N">Neuropsychiatric systemic lupus erythematosus (NPLSE)</Keyword><Keyword MajorTopicYN="N">Pediatric</Keyword><Keyword MajorTopicYN="N">Plasma cell</Keyword><Keyword MajorTopicYN="N">Psychosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36971919</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06559-y</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06559-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schwartz N, Stock AD, Putterman C (2019) Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 15(3):137&#x2013;152. https://doi.org/10.1038/s41584-018-0156-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0156-8</ArticleId><ArticleId IdType="pubmed">30659245</ArticleId><ArticleId IdType="pmc">8023338</ArticleId></ArticleIdList></Reference><Reference><Citation>Pego-Reigosa JM, Isenberg DA (2008) Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford, England) 47(10):1498&#x2013;1502. https://doi.org/10.1093/rheumatology/ken260</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ken260</ArticleId><ArticleId IdType="pubmed">18658205</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu TY, Tam LS, Lee VW, Lee KK, Li EK (2009) The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 61(9):1159&#x2013;1167. https://doi.org/10.1002/art.24725</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24725</ArticleId><ArticleId IdType="pubmed">19714597</ArticleId></ArticleIdList></Reference><Reference><Citation>Giani T, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, Davidson J, Gardner-Medwin J, Haslam K, Hawley DP, Leahy A, Leone V, McErlane F, Mewar D, Modgil G, Moots R, Pilkington C, Pregnolato F, Ramanan AV, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Cimaz R, Beresford MW, Hedrich CM (2021) Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus 30(12):1955&#x2013;1965. https://doi.org/10.1177/09612033211045050</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211045050</ArticleId><ArticleId IdType="pubmed">34601989</ArticleId><ArticleId IdType="pmc">8649437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolucci P, Br&#xe9;chignac S, Cohen P, Le Guern V, Guillevin L (2007) Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus 16(10):817&#x2013;822. https://doi.org/10.1177/0961203307081840</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307081840</ArticleId><ArticleId IdType="pubmed">17895305</ArticleId></ArticleIdList></Reference><Reference><Citation>Narv&#xe1;ez J, R&#xed;os-Rodriguez V, de la Fuente D, Estrada P, L&#xf3;pez-Vives L, G&#xf3;mez-Vaquero C, Nolla JM (2011) Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum 41(3):364&#x2013;372. https://doi.org/10.1016/j.semarthrit.2011.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2011.06.004</ArticleId><ArticleId IdType="pubmed">21875742</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer BF, Manz RA, Radbruch A, Hiepe F (2005) Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 1050:124&#x2013;133. https://doi.org/10.1196/annals.1313.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1313.014</ArticleId><ArticleId IdType="pubmed">16014527</ArticleId></ArticleIdList></Reference><Reference><Citation>Streicher K, Morehouse CA, Groves CJ, Rajan B, Pilataxi F, Lehmann KP, Brohawn PZ, Higgs BW, McKeever K, Greenberg SA, Fiorentino D, Richman LK, Jallal B, Herbst R, Yao Y, Ranade K (2014) The plasma cell signature in autoimmune disease. Arthritis Rheumatol (Hoboken, NJ) 66(1):173&#x2013;184. https://doi.org/10.1002/art.38194</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiepe F, D&#xf6;rner T, Hauser AE, Hoyer BF, Mei H, Radbruch A (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7(3):170&#x2013;178. https://doi.org/10.1038/nrrheum.2011.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2011.1</ArticleId><ArticleId IdType="pubmed">21283146</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiepe F, Radbruch A (2016) Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol 12(4):232&#x2013;240. https://doi.org/10.1038/nrneph.2016.20</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.20</ArticleId><ArticleId IdType="pubmed">26923204</ArticleId></ArticleIdList></Reference><Reference><Citation>Khodadadi L, Cheng Q, Alexander T, Sercan-Alp O, Klotsche J, Radbruch A, Hiepe F, Hoyer BF, Taddeo A (2015) Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 mice. PloS one 10(8):e0135081. https://doi.org/10.1371/journal.pone.0135081</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0135081</ArticleId><ArticleId IdType="pubmed">26252021</ArticleId><ArticleId IdType="pmc">4529137</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow WR, Frazier EA, Mahle WT, Harville TO, Pye SE, Knecht KR, Howard EL, Smith RN, Saylors RL, Garcia X, Jaquiss RD, Woodle ES (2012) Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 93(3):319&#x2013;324. https://doi.org/10.1097/TP.0b013e31823f7eea</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e31823f7eea</ArticleId><ArticleId IdType="pubmed">22179403</ArticleId><ArticleId IdType="pmc">3730122</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinn MD, L&#x2019;Ecuyer TJ, Fagoaga OR, Aggarwal S (2014) Bortezomib use in a pediatric cardiac transplant center. Pediatr Transplant 18(5):469&#x2013;476. https://doi.org/10.1111/petr.12300</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/petr.12300</ArticleId><ArticleId IdType="pubmed">24931171</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez AM, Willcox N, Vrolix K, Hummel J, Nogales-Gadea G, Saxena A, Duimel H, Verheyen F, Molenaar PC, Buurman WA, De Baets MH, Martinez-Martinez P, Losen M (2014) Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. Journal of immunology (Baltimore, Md&#x202f;: 1950) 193(3):1055&#x2013;1063. https://doi.org/10.4049/jimmunol.1301555</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301555</ArticleId><ArticleId IdType="pubmed">24973445</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhou W, Zhang Z (2015) Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient. Rheumatology (Oxford, England) 54(1):194&#x2013;195. https://doi.org/10.1093/rheumatology/keu393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu393</ArticleId><ArticleId IdType="pubmed">25288787</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AH (2014) Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant&#x202f;: J Am Soc Blood Marrow Transplant 20(10):1654&#x2013;1659. https://doi.org/10.1016/j.bbmt.2014.06.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2014.06.032</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Sarfert R, Klotsche J, Kuhl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74(7):1474&#x2013;1478. https://doi.org/10.1136/annrheumdis-2014-206016</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206016</ArticleId><ArticleId IdType="pubmed">25710470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, Shirota Y, Shirai T, Fujita Y, Watanabe R, Chiu SW, Yamaguchi T, Harigae H (2018) Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol 28(6):986&#x2013;992. https://doi.org/10.1080/14397595.2018.1432331</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1432331</ArticleId><ArticleId IdType="pubmed">29363990</ArticleId></ArticleIdList></Reference><Reference><Citation>Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, Ramos N, Carnicer C, Valtierra N, Ostos E (2020) Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus 29(2):118&#x2013;125. https://doi.org/10.1177/0961203319896018</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319896018</ArticleId><ArticleId IdType="pubmed">31865857</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkachenko O, Lapin S, Maslyansky A, Myachikova V, Mikhailova L, Gilburd B (2019) Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with Bortezomib in combination with plasma exchange. Clin Immunol 199:44&#x2013;46. https://doi.org/10.1016/j.clim.2018.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2018.12.010</ArticleId><ArticleId IdType="pubmed">30543928</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibe F, Pruss H, Mengel AM, Kohler S, Numann A, Kohnlein M, Ruprecht K, Alexander T, Hiepe F, Meisel A (2017) Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 88(4):366&#x2013;370. https://doi.org/10.1212/wnl.0000000000003536</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000003536</ArticleId><ArticleId IdType="pubmed">28003505</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin YW, Lee ST, Kim TJ, Jun JS, Chu K (2018) Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis. Ann Clin Transl Neurol 5(5):598&#x2013;605. https://doi.org/10.1002/acn3.557</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.557</ArticleId><ArticleId IdType="pubmed">29761122</ArticleId><ArticleId IdType="pmc">5945964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Tian DC, Yang CS, Han B, Wang J, Yang L, Shi FD (2017) Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol 74(8):1010&#x2013;1012. https://doi.org/10.1001/jamaneurol.2017.1336</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1336</ArticleId><ArticleId IdType="pubmed">28692708</ArticleId><ArticleId IdType="pmc">5822186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH (2018) Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms? JAMA Neurol 75(1):128&#x2013;129. https://doi.org/10.1001/jamaneurol.2017.3447</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.3447</ArticleId><ArticleId IdType="pubmed">29159372</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, Isenberg D, Alarc&#xf3;n GS, Straaton KV, Denburg J, Denburg S, Esdaile JM, Glanz BI, Karlson EW, Khoshbin S, Rogers MP, Schur PH, Hanly JG, Kozora E, West S, Lahita RG, Lockshin MD, McCune J, Moore PM, Petri M, Roberts WN, Sanchez-Guerrero J, Veilleux M, Brey R, Cornblath WD, Filley CM, Fisk JD, Harten P, Hay EM, Iverson G, Levine SR, Waterhouse E, Wallace DJ, Winer JB (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42(4)599&#x2013;608.&#xa0; https://doi.org/10.1002/1529-0131(199904)42:4&lt;599::Aid-anr2&gt;3.0.Co;2-f</Citation></Reference><Reference><Citation>Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431&#x2013;440. https://doi.org/10.1016/s1470-2045(11)70081-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(11)70081-x</ArticleId><ArticleId IdType="pubmed">21507715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla-Abad&#xed;a F, Coronel Restrepo N, Tob&#xf3;n GJ, Echeverri AF, Mu&#xf1;oz-Buitr&#xf3;n E, Castro AM, Bejarano MA, Ca&#xf1;as CA (2014) Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus. Autoimmune Dis 2014:731806. https://doi.org/10.1155/2014/731806</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/731806</ArticleId><ArticleId IdType="pubmed">24527208</ArticleId><ArticleId IdType="pmc">3914290</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler NH (2011) Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma. P t 36(9):590&#x2013;598</Citation><ArticleIdList><ArticleId IdType="pubmed">22346327</ArticleId><ArticleId IdType="pmc">3278141</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner HI, Higgins GC, Klein-Gitelman MS, Lapidus SK, Olson JC, Onel K, Punaro M, Ying J, Giannini EH (2010) Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62(7):950&#x2013;959. https://doi.org/10.1002/acr.20154</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20154</ArticleId><ArticleId IdType="pubmed">20589695</ArticleId></ArticleIdList></Reference><Reference><Citation>Mike EV, Makinde HM, Der E, Stock A, Gulinello M, Gadhvi GT, Winter DR, Cuda CM, Putterman C (2018) Neuropsychiatric systemic lupus erythematosus is dependent on sphingosine-1-phosphate signaling. Front Immunol 9:2189. https://doi.org/10.3389/fimmu.2018.02189</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02189</ArticleId><ArticleId IdType="pubmed">30319641</ArticleId><ArticleId IdType="pmc">6168636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH (2012) Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64(2):493&#x2013;503. https://doi.org/10.1002/art.33333</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.33333</ArticleId><ArticleId IdType="pubmed">21905015</ArticleId><ArticleId IdType="pmc">4584406</ArticleId></ArticleIdList></Reference><Reference><Citation>Griger Z, Toth BI, Barath S, Gyetvai A, Kovacs I, Tarr T, Biro T, Zeher M, Sipka S (2012) Different effects of bortezomib on the expressions of various protein kinase C isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells. Scand J Immunol 75(2):243&#x2013;248. https://doi.org/10.1111/j.1365-3083.2011.02647.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.2011.02647.x</ArticleId><ArticleId IdType="pubmed">21988336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohty M, Brissot E, Savani BN, Gaugler B (2013) Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant&#x202f;: J Am Soc Blood Marrow Transplant 19(10):1416&#x2013;1420. https://doi.org/10.1016/j.bbmt.2013.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2013.05.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D (2015) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 74(11):2006&#x2013;2015. https://doi.org/10.1136/annrheumdis-2013-205067</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205067</ArticleId><ArticleId IdType="pubmed">24951103</ArticleId></ArticleIdList></Reference><Reference><Citation>(2022) Benlysta (belimumab) [package insert]. GlaxoSmithKline, Philadelphia, PA</Citation></Reference><Reference><Citation>Pl&#xfc;&#xdf; M, Tampe B, Niebusch N, Zeisberg M, M&#xfc;ller GA, Korsten P (2020) Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med 7(222). https://doi.org/10.3389/fmed.2020.00222</Citation></Reference><Reference><Citation>Sj&#xf6;wall C, Hjorth M, Eriksson P (2017) Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus 26(12):1333&#x2013;1338. https://doi.org/10.1177/0961203317691371</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317691371</ArticleId><ArticleId IdType="pubmed">28162031</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R, Hoyer BF, Burmester GR, Radbruch A, Hiepe F (2018) Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol 48(9):1573&#x2013;1579. https://doi.org/10.1002/eji.201847492</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847492</ArticleId><ArticleId IdType="pubmed">29979809</ArticleId></ArticleIdList></Reference><Reference><Citation>(2022) Velcade (bortezomib) [package insert]. Takeda Pharmaceuticals America Inc,&#xa0;Lexington, MA</Citation></Reference><Reference><Citation>Huehnchen P, Springer A, Kern J, Kopp U, Kohler S, Alexander T, Hiepe F, Meisel A, Boehmerle W, Endres M (2020) Bortezomib at therapeutic doses poorly passes the blood-brain barrier and does not impair cognition. Brain Commun 2(1):fcaa021. https://doi.org/10.1093/braincomms/fcaa021</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa021</ArticleId><ArticleId IdType="pubmed">32954282</ArticleId><ArticleId IdType="pmc">7425526</ArticleId></ArticleIdList></Reference><Reference><Citation>Karageorgas TP, Tseronis DD, Mavragani CP (2011) Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes. J Biomed Biotechnol 2011:273907. https://doi.org/10.1155/2011/273907</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/273907</ArticleId><ArticleId IdType="pubmed">22162633</ArticleId><ArticleId IdType="pmc">3227532</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD (2009) Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant&#x202f;: Off J Am Soc Transplant Am Soc Transplant Surg 9(1):201&#x2013;209. https://doi.org/10.1111/j.1600-6143.2008.02461.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2008.02461.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohlich K, Holle JU, Aries PM, Gross WL, Moosig F (2011) Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 70(7):1344&#x2013;1345. https://doi.org/10.1136/ard.2010.133256</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.133256</ArticleId><ArticleId IdType="pubmed">21173019</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartuccio L, Rupolo M, Michieli M, De Vita S (2014) Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. Rheumatology (Oxford, England) 53(2):381&#x2013;382. https://doi.org/10.1093/rheumatology/ket284</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket284</ArticleId><ArticleId IdType="pubmed">23962626</ArticleId></ArticleIdList></Reference><Reference><Citation>Taddeo A, Khodadadi L, Voigt C, Mumtaz IM, Cheng Q, Moser K, Alexander T, Manz RA, Radbruch A, Hiepe F, Hoyer BF (2015) Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res Ther 17(1):39. https://doi.org/10.1186/s13075-015-0551-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0551-3</ArticleId><ArticleId IdType="pubmed">25889236</ArticleId><ArticleId IdType="pmc">4411657</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann K, Clauder AK, Manz RA (2018) Targeting B cells and plasma cells in autoimmune diseases. Front Immunol 9:835. https://doi.org/10.3389/fimmu.2018.00835</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00835</ArticleId><ArticleId IdType="pubmed">29740441</ArticleId><ArticleId IdType="pmc">5924791</ArticleId></ArticleIdList></Reference><Reference><Citation>Groettrup M, Kirk CJ, Basler M (2010) Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 10(1):73&#x2013;78. https://doi.org/10.1038/nri2687</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2687</ArticleId><ArticleId IdType="pubmed">20010787</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, Knebel F, Burmester G, Radbruch A, Mei HE, Mashreghi MF, Hiepe F, Alexander T (2020) Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med 383(12):1149&#x2013;1155. https://doi.org/10.1056/NEJMoa2023325</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023325</ArticleId><ArticleId IdType="pubmed">32937047</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei HE, Schmidt S, D&#xf6;rner T (2012) Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther 14(Suppl 5):S1. https://doi.org/10.1186/ar3909</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3909</ArticleId><ArticleId IdType="pubmed">23281743</ArticleId><ArticleId IdType="pmc">3535716</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382(3):211&#x2013;221. https://doi.org/10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>